ProMetic Life Sciences Inc. (PLI) Price Target Lowered to C$3.50 at TD Securities
ProMetic Life Sciences Inc. (TSE:PLI) had its price target cut by equities researchers at TD Securities from C$4.50 to C$3.50 in a research report issued on Wednesday. The firm currently has a “speculative buy” rating on the stock. TD Securities’ target price would indicate a potential upside of 155.47% from the stock’s previous close.
Other equities analysts have also issued reports about the stock. Canaccord Genuity reduced their target price on shares of ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research report on Monday, June 19th. Scotiabank reduced their target price on shares of ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a research report on Friday, July 7th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of ProMetic Life Sciences in a research report on Wednesday, May 24th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. ProMetic Life Sciences currently has a consensus rating of “Buy” and an average target price of C$4.07.
ProMetic Life Sciences (TSE:PLI) traded down 6.57% on Wednesday, hitting $1.28. The company’s stock had a trading volume of 1,073,858 shares. The firm has a 50 day moving average of $1.58 and a 200 day moving average of $2.01. ProMetic Life Sciences has a 12 month low of $1.17 and a 12 month high of $3.24. The firm’s market cap is $855.94 million.
COPYRIGHT VIOLATION NOTICE: “ProMetic Life Sciences Inc. (PLI) Price Target Lowered to C$3.50 at TD Securities” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/16/prometic-life-sciences-inc-pli-price-target-lowered-to-c3-50-at-td-securities.html.
In related news, Director Louise Ménard sold 82,202 shares of ProMetic Life Sciences stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of C$1.60, for a total transaction of C$131,523.20. Over the last three months, insiders have purchased 28,424 shares of company stock worth $56,809.
About ProMetic Life Sciences
ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.